"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 3 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 7 | 10 |
| 2011 | 5 | 2 | 7 |
| 2012 | 5 | 5 | 10 |
| 2013 | 11 | 7 | 18 |
| 2014 | 4 | 5 | 9 |
| 2015 | 1 | 6 | 7 |
| 2016 | 3 | 13 | 16 |
| 2017 | 5 | 7 | 12 |
| 2018 | 4 | 10 | 14 |
| 2019 | 11 | 8 | 19 |
| 2020 | 6 | 8 | 14 |
| 2021 | 14 | 9 | 23 |
| 2022 | 2 | 18 | 20 |
| 2023 | 4 | 13 | 17 |
| 2024 | 15 | 14 | 29 |
| 2025 | 3 | 11 | 14 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers. Ann Surg Oncol. 2025 Oct; 32(11):8256-8268.
-
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
-
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Oct; 32(11):8211-8219.
-
Utilizing Patient Input in Rectal Cancer Trial Design. J Natl Cancer Inst. 2025 Jul 01; 117(7):1421-1428.
-
Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e481060.
-
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat Med. 2025 Jul; 31(7):2397-2404.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025 Sep; 169(4):585-599.